Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Diabetes, Hypertension, Hyperlipidemia, Heart Diseases, Depression, Psychoses
Interventions: pharmacist contact with the patient via telephone, Pharmacist contact with the patient's physician via fax, Usual care; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: Not listed
Enrollment: 3,048 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: Placebo, Statin, PF-04950615 (RN316), Satin; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 38
States / cities: Tustin, California • Walnut Creek, California • Clearwater, Florida + 25 more

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 16
States / cities: Anaheim, California • Mission Viejo, California • Westlake Village, California + 12 more

Conditions: Familial Hypercholesterolemia
Interventions: Cascade screening; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertriglyceridemia
Interventions: Gemfibrozil; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 19 Years to 74 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hyperlipidemia
Interventions: LY3015014 IV, Placebo IV, LY3015014 SC, Placebo SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Glendale, California • Dallas, Texas • Madison, Wisconsin

Conditions: Cardiovascular Risk Factor, Lipemia
Interventions: High-fat meal; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hyperlipidemias
Interventions: Bempedoic Acid + Ezetimibe Fixed-Dose Combination, Bempedoic Acid, Ezetimibe, Placebos; Combination Product · Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: Not listed
Lead sponsor: The Rogosin Institute; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Familial Hypercholesterolemia
Interventions: Cascade Screening; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hyperlipidemias
Interventions: Bean powder, Rice bran, Control arm, Bean powder and rice bran; Dietary Supplement
Lead sponsor: Poudre Valley Health System; Other
Eligibility: 8 Years to 13 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Fort Collins, Colorado • Loveland, Colorado

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia
Interventions: Obicetrapib 5mg, Ezetimibe 10mg, Placebo; Drug · Other
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 3
States / cities: Lincoln, California • Evanston, Illinois • Houston, Texas

Conditions: Dyslipidemia, Healthy Volunteers
Interventions: TAP311; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Hyperlipidemia
Interventions: Omega-3 fatty acid (Eicosapentaenoic acid); Dietary Supplement
Lead sponsor: University of California, San Francisco; Other
Eligibility: 8 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 1 Hyperlipoproteinemia
Interventions: SLx-4090 placebo, Orlistat Placebo, Orlistat, Slx-4090; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 12 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Time Restricted Eating, Obstructive Sleep Apnea
Interventions: Time restricted eating; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Cardiovascular Disease, Hyperlipidemia
Interventions: Evolocumab, 18F-NaF PET, CCTA, Omnipaque, Metoprolol, Nitroglycerin; Drug · Diagnostic Test
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Insulin Resistance, Obesity, Cardiovascular Diseases, Cognitive Impairment, Physical Disability, Depression, Inflammation, Hormone Deficiency, Physical Inactivity, Hyperlipidemias, Hypertension, Overeating
Interventions: GLY-LOW; Biological
Lead sponsor: Hoskinson Health and Wellness Clinic; Industry
Eligibility: 56 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Gillette, Wyoming

Conditions: Hyperlipidemia, Pregnancy
Interventions: Lipid panel; Diagnostic Test
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypercholesterolemia
Interventions: Placebo (for alirocumab), Alirocumab, Statin; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 49
States / cities: Chandler, Arizona • Goodyear, Arizona • Carmichael, California + 46 more

Conditions: Colorectal Cancer, High Cholesterol
Interventions: Good high cholesterol video, Poor high cholesterol video, Good colon cancer screening video, Poor colon cancer screening video; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 401 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non Alcoholic Fatty Liver Disease, Steatohepatitis, Hypertriglyceridemia, Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1
Interventions: Omega diet; Other
Lead sponsor: Yale University; Other
Eligibility: 10 Years to 19 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: High Cholesterol
Interventions: Policosanol, Placebo, Policosanol Plus Already In Use Statin Therapy; Drug · Other
Lead sponsor: James Backes, PharmD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Obesity, Diabetes, Hyperlipidemia
Interventions: Oleic acid (OA), Palmitic Acid (PA); Dietary Supplement
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 35 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Galveston, Texas

Search by objective public record fields.

Pharmacy Interventions to Improve Chronic Disease Medication Refill

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects

Penn Family Screening for Familial Hypercholesterolemia

Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides

A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol

Postprandial Monocyte Maturation and Vascular Dysfunction Following High-Fat Meals - Study 1

A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy

The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository

Equitable Implementation of Cascade Screening for Familial Hypercholesterolemia

Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children

Randomized Study of Obicetrapib in Combination With Ezetimibe

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

The Effects of a Mediterranean Diet in Pediatric Hyperlipidemia

Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia

Time Restricted Eating in Sleep Apnea

Effect of Evolocumab on Coronary Atherosclerosis

Pilot Study of GLY-LOW Supplementation in Postmenopausal Women With Obesity

Lipid Profile as Predictor of Adverse Maternal and Neonatal Outcomes: A Pilot Study

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)

Online Trial Examining Validity of the Shared Decision Making Process Survey With Video Vignettes

Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease

Effect of Policosanol as Monotherapy and Adjunctive to Statin Therapy

Differential Metabolism of Dietary Fatty Acids